Suspendido

The Effect of Ureteric Stent Tethers on Patient Symptoms, Stent Bacterial Colonization and Urinary Tract Infection

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está evaluando

Double J-stent with a long tether

+ Double J-stent without a long tether

Dispositivo
Quiénes están siendo reclutados

Enfermedades Urogenitales+5

+ Cálculos

+ Enfermedades Urogenitales Femeninas y Complicaciones del Embarazo

A partir de 18 años
+15 Criterios de eligibilidad
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Estudio de Tratamiento

Intervencional
Inicio del estudio: marzo de 2013
Ver detalles del protocolo

Resumen

Patrocinador PrincipalUnity Health Toronto
Última actualización: 21 de mayo de 2015
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 1 de marzo de 2013

Fecha en la que se inscribió al primer participante.

Two of the main issues surrounding the use of ureteral stents are stent related symptoms and bacterial colonization/urinary tract infection (UTI). To be useful, stent tethers must decrease the morbidity associated with stent removal and the cost to the health care system, while not increasing stent related symptoms or UTI. To our knowledge, the effect of leaving a stent tether on stent symptoms and bacterial colonization of the stent and urine has not been previously studied. This is a single-centre, prospective, randomized, controlled trial. Patients eligible for recruitment into the study based on the inclusion and exclusion criteria will be provided with a consent form at the time of their initial appointment, when their ureteroscopy is being booked. Once consent is obtained, patients will be randomized (using random number table look-up) to receive either double-J stent placement with a tether (the Treatment Group) or double-J stent placement without a tether (the Control Group) following ureteroscopy. Randomization will occur prior to the commencement of ureteroscopy. Patients will either have a double J-stent placed with or without a long tether attached. The double-J stents used in the treatment and control groups will be otherwise identical. All stents will be 6 French in diameter and 22-26 cm in length based on the patients' height. Sizing of stent length will be performed uniformly in the treatment and control group and will involve measuring ureteric length from the ureteropelvic junction to ureterovesical junction with a marked ureteral catheter. All patients will receive a single preoperative dose of prophylactic antibiotics (i.e., Ampicillin and Gentamicin or Ciprofloxacin).All patients will have a urine sample collected for culture and sensitivity at the start of the procedure. Blinding will not be feasible during this trial due to the nature of the intervention. The urologist performing the procedure will clearly be aware of whether a tether is left on the stent. Similarly, patients will also be aware of whether a string tether is protruding from their urethral meatus or not. However, assessors of the compiled data and questionnaires will be blinded to the intervention. Once enrolled in the study, patients will be given the Ureteral Stent Symptoms Questionnaire 1 (Pre Stent) to complete prior to undergoing ureteroscopy and stent insertion. This will allow us to establish baseline lower urinary tract symptoms. After completion of ureteroscopy and stent insertion and upon discharge from the hospital all patients will be provided with the following: Diary sheets to record daily analgesic use A prescription for a standardized analgesic regimen including Percocet (1 tablet PO q6h prn, 20 tablets) to be taken as needed for pain control. An appointment for the first follow-up visit (in 7-14 days) At the follow-up visit, a kidney, ureter and bladder (KUB) radiograph will be performed and patients will complete the Ureteral Stent Symptoms Questionnaire 2 (Stent insitu). The KUB x-ray will be reviewed to ensure the stent remained in appropriate position and did not migrate and that any residual stone fragments have passed. Next, all patients will have their stent removed. Patients in the control group will undergo cystoscopy under local anesthesia for stent removal and those the treatment group will have the stent removed by the tether. This distal curl or lower end (bladder) of the double-J stent, in all patients, will be sent to microbiology for culture to determine the rate of stent bacterial colonization. Of note, all patients in the control group will provide a mid-stream urine sample to be sent for culture and sensitivity testing, after cystoscopy and stent removal, while all patients in the treatment group will provide a urine sample after the stent is removed, so the tether does not contaminate the sample. This urine sample will allow us to establish the rate of bacteriuria. Upon discharge from the Cystoscopy unit following stent removal all patients will return for a final follow-up with renal ultrasound approximately 4-6 weeks post-stent removal and will be given the Ureteral Stent Symptoms Questionnaire 3 (Post Stent) to complete.

Patrocinador PrincipalUnity Health Toronto
Última actualización: 21 de mayo de 2015
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 11 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Estudio de Tratamiento

Estos estudios prueban nuevas formas de tratar una enfermedad, condición o problema de salud. El objetivo es determinar si un nuevo medicamento, terapia o enfoque funciona mejor o tiene menos efectos secundarios que las opciones existentes.



Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

A partir de 18 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Enfermedades UrogenitalesCálculosEnfermedades Urogenitales Femeninas y Complicaciones del EmbarazoEnfermedades RenalesCondiciones Patológicas, Signos y SíntomasCálculos UrinariosEnfermedades UrológicasCálculos renales

Criterios

4 criterios de inclusión requeridos para participar
Age over 18 years

First presentation for ureteroscopy for this particular stone

Follow-up conducted at St. Michael's Hospital

Planned insertion of a double J-stent

11 criterios de exclusión impiden participar
Active urinary tract infection or positive screening urine culture at preadmission

Age < 18years

Bilateral ureteric stents to be inserted

Patient currently taking an α-blocker (alfuzosin, terazosin,tamsulosin, prazosin)

Mostrar Más Criterios

Plan de Estudio

Conoce todos los tratamientos administrados en este estudio, su descripción detallada y en qué consisten.
Grupos de Tratamiento
Objetivos del Estudio

2 grupos de intervención están designados en este estudio

0% de probabilidad de ser asignado al grupo placebo

Grupos de Tratamiento

Grupo I

Experimental
Following ureteroscopy patients will have placed a double J-stent with a long tether.

Grupo II

Comparador Activo
Following ureteroscopy patients will have a double J-stent placed without a long tether

Objetivos del Estudio

Objetivos Primarios

Objetivos Secundarios

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene una ubicación

St. Michael Hospital

Toronto, CanadaAbrir St. Michael Hospital en Google Maps
Suspendido1 Centros de Estudio